Atrium Therapeutics Q3 2026 net loss widens to $4.27 million

By Public Technologies
  • Atrium Therapeutics’ third-quarter 2026 net loss widened to $4.27 million from a year earlier.
  • Collaboration revenue rose 24% year over year to $15.32 million, primarily related to a Bristol Myers Squibb milestone.
  • Total operating expenses climbed 75% year over year to $21.95 million.
  • The first patient was dosed in Corventis, the ATR 1072 Phase 1/2 trial; initial proof-of-concept data are expected in second-half 2027.
  • Cash, cash equivalents and short-term investments totaled $232.1 million at September 30; anticipated cash runway extends through 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA96095) on November 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.